Business
Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research
RAHWAY, N.J., March 16, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new clinical data from the company’s cardio-pulmonary pipeline will be presented at the American College of Cardiology’s Annual Scientific Session and Expo (ACC.26) in New Orleans, La., from March 28-30. The results shared will highlight Merck’s unwavering commitment to advancing innovative research in hypercholesterolemia and in the syndrome of combined post- and precapillary p
About this update from Merck & Company, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":217,"url":"https://media.zenfs.com/en/business-wire.com/6e666150e87b871a8a34cc3e54b4ddce"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NuwvzmJkl.zseOgTHRMBFA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQzNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6e666150e87b871a8a34cc3e54b4ddce","width":480,"height":217}},"lazy":false},{"type":"text","content":"Late-breaking presentation of results from the Phase 3 CORALreef AddOn trial evaluating enlicitide decanoate, Merck’s investigational oral PCSK9 inhibitor, which may help address the cardiovascular (CV) epidemic","length":211,"tagName":"p","attribs":{}},{"type":"text","content":"Data from the Phase 2 CADENCE trial of WINREVAIRTM (sotatercept-csrk) in patients with the syndrome of combined post- and precapillary pulmonary hypertension and heart failure with preserved ejection fraction (CpcPH-HFpEF) to be featured as late-breaking presentation","length":267,"tagName":"p","attribs":{}},{"type":"text","content":"RAHWAY, N.J., March 16, 2026--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new clinical data from the company’s cardio-pulmonary pipeline will be presented at the American College of Cardiology’s Annual Scientific Session and Expo (ACC.26) in New Orleans, La., from March 28-30. The results shared will highlight Merck’s unwavering commitment to advancing innovative research in hypercholesterolemia and in the syndrome of combined post- and precapillary pulmonary hypertension and heart failure with preserved ejection fraction (CpcPH-HFpEF) to help address the significant burden of these diseases.","length":661,"tagName":"p"},{"type":"text","content":"Key data being shared include two late-breaking presentations:","length":62,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Positive results from the Phase 3 CORALreef AddOn trial evaluating the efficacy and safety of enlicitide, an investigational, once-daily oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor versus ezetimibe, versus bempedoic acid and versus ezetimibe and bempedoic acid in adults with hypercholesterolemia who are treated with a statin;","length":352,"tagName":"p","...